Literature DB >> 24947467

Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.

Yasuo Uchida1, Kentaro Wakayama1, Sumio Ohtsuki1, Masato Chiba1, Tomoyuki Ohe1, Yasuyuki Ishii1, Tetsuya Terasaki2.   

Abstract

The aim of this study was to investigate whether in vivo drug distribution in brain in monkeys can be reconstructed by integrating four factors: protein expression levels of P-glycoprotein (P-gp)/multidrug resistance protein 1 at the blood-brain barrier (BBB), in vitro transport activity per P-gp molecule, and unbound drug fractions in plasma and brain. For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells. In vivo P-gp functions at the BBB were reconstructed from in vitro P-gp transport activities and P-gp expression levels in transfected cells and cynomolgus brain microvessels. Brain-to-plasma concentration ratios (Kp,brain) were reconstructed by integrating the reconstructed in vivo P-gp functions with drug unbound fractions in plasma and brain. For all compounds, the reconstructed Kp,brain values were within a 3-fold range of observed values, as determined by constant intravenous infusion in adult cynomolgus monkeys. Among four factors, plasma unbound fraction was the most sensitive factor to species differences in Kp,brain between monkeys and mice. Unbound brain-to-plasma concentration ratios (Kp,uu,brain) were reconstructed as the reciprocal of the reconstructed in vivo P-gp functions, and the reconstructed Kp,uu,brain values were within a 3-fold range of in vivo values, which were estimated from observed Kp,brain and unbound fractions. This study experimentally demonstrates that brain distributions of P-gp substrates and nonsubstrate can be reconstructed on the basis of pharmacoproteomic concept in monkeys, which serve as a robust model of drug distribution in human brain.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24947467     DOI: 10.1124/jpet.114.214536

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

2.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Authors:  Yingying Guo; Xiaoyan Chu; Neil J Parrott; Kim L R Brouwer; Vicky Hsu; Swati Nagar; Pär Matsson; Pradeep Sharma; Jan Snoeys; Yuichi Sugiyama; Daniel Tatosian; Jashvant D Unadkat; Shiew-Mei Huang; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2018-09-12       Impact factor: 6.875

3.  Regional Differences in the Absolute Abundance of Transporters, Receptors and Tight Junction Molecules at the Blood-Arachnoid Barrier and Blood-Spinal Cord Barrier among Cervical, Thoracic and Lumbar Spines in Dogs.

Authors:  Hina Takeuchi; Masayoshi Suzuki; Ryohei Goto; Kenta Tezuka; Holger Fuchs; Naoki Ishiguro; Tetsuya Terasaki; Clemens Braun; Yasuo Uchida
Journal:  Pharm Res       Date:  2022-04-29       Impact factor: 4.200

4.  Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.

Authors:  Christopher Rowbottom; Alicia Pietrasiewicz; Taras Tuczewycz; Richard Grater; Daniel Qiu; Sudarshan Kapadnis; Patrick Trapa
Journal:  Pharmacol Res Perspect       Date:  2021-04

Review 5.  Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery.

Authors:  Kristiina M Huttunen; Tetsuya Terasaki; Arto Urtti; Ahmed B Montaser; Yasuo Uchida
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.580

6.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

7.  Construction and Functional Evaluation of a Three-Dimensional Blood-Brain Barrier Model Equipped With Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells.

Authors:  Toshiki Kurosawa; Daiki Sako; Yuma Tega; Yasuyuki Debori; Yumi Tomihara; Kazunobu Aoyama; Yoshiyuki Kubo; Nobuyuki Amano; Yoshiharu Deguchi
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

Review 8.  ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas.

Authors:  David Gomez-Zepeda; Méryam Taghi; Jean-Michel Scherrmann; Xavier Decleves; Marie-Claude Menet
Journal:  Pharmaceutics       Date:  2019-12-23       Impact factor: 6.321

9.  Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood-Brain Barrier in Non-Human Primates with PET.

Authors:  Lara García-Varela; Wejdan M Arif; David Vállez García; Takeharu Kakiuchi; Hiroyuki Ohba; Norihiro Harada; Tetsuro Tago; Philip H Elsinga; Hideo Tsukada; Nicola Antonio Colabufo; Rudi A J O Dierckx; Aren van Waarde; Jun Toyohara; Ronald Boellaard; Gert Luurtsema
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

10.  Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.

Authors:  Olena Anoshchenko; Flavia Storelli; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-08-23       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.